Oppenheimer Cuts CalciMedica (NASDAQ:CALC) Price Target to $10.00

CalciMedica (NASDAQ:CALC) had its target price reduced by Oppenheimer from $20.00 to $10.00 in a report issued on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

CALC has been the topic of a number of other research reports. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a report on Thursday, January 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a research report on Wednesday, January 21st. Finally, Wall Street Zen upgraded CalciMedica to a “sell” rating in a research note on Saturday, January 17th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $13.00.

CalciMedica Stock Performance

Shares of CalciMedica stock opened at $0.73 on Thursday. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The firm’s 50-day moving average is $2.86 and its 200 day moving average is $3.33. The stock has a market cap of $11.44 million, a price-to-earnings ratio of -0.45 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 3.58 and a quick ratio of 4.04.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.69) earnings per share for the quarter. Sell-side analysts anticipate that CalciMedica will post -2.21 EPS for the current fiscal year.

Institutional Trading of CalciMedica

A number of large investors have recently made changes to their positions in CALC. Sound View Wealth Advisors Group LLC purchased a new position in shares of CalciMedica during the second quarter valued at approximately $32,000. Cetera Investment Advisers boosted its holdings in CalciMedica by 33.1% in the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares during the last quarter. Atria Investments Inc grew its position in CalciMedica by 20.0% in the 2nd quarter. Atria Investments Inc now owns 44,700 shares of the company’s stock worth $72,000 after purchasing an additional 7,436 shares during the period. Jane Street Group LLC bought a new stake in CalciMedica in the 4th quarter worth approximately $127,000. Finally, Envestnet Asset Management Inc. raised its stake in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the last quarter.

Key Stories Impacting CalciMedica

Here are the key news stories impacting CalciMedica this week:

• Positive Sentiment: HC Wainwright raised its FY2027 and FY2028 EPS forecasts (FY2027 to $(0.86) from $(1.06); FY2028 to $(0.98) from $(1.20)), reducing projected losses in later years — a constructive signal for long‑term outlook. HC Wainwright estimates
• Neutral Sentiment: HC Wainwright kept a “Neutral” rating while publishing detailed quarterly EPS estimates for 2026 (Q1 $(0.31), Q2 $(0.33), Q3 $(0.37), Q4 $(0.43)) and revised FY2026 to $(1.45) — the near‑term outlook remains loss‑making, so catalyst timing is unclear. HC Wainwright estimates
• Neutral Sentiment: Short‑interest filings reported 0 shares outstanding short and a 0.0 days‑to‑cover figure — described as a “large increase” in the feed but numerically inconsistent (NaN/0). This looks like a data/reporting anomaly rather than a confirmed short squeeze or heavy shorting pressure. No direct link available.
• Negative Sentiment: Oppenheimer cut its price target sharply from $20 to $10 (while keeping an “Outperform” rating), which is a notable downward revision of expected upside and may weigh on sentiment despite the retained bullish rating. Oppenheimer price target cut Additional coverage

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.